

Statement

Rapid SARS-CoV-2 Antigen Test Card manufactured by Xiamen Boson Biotech Co., Ltd. detects the nucleocapsid protein (N protein). It does not target the spike protein (S protein) of genetic SARS-CoV-2 variants. Therefore, theoretically, mutations in the spike protein do not affect the product performance, and our test can detect the mutant SARS-CoV-2 strains.

The following variant strains of the SARS-CoV-2 virus with mutations in the nucleocapsid protein have been evaluated to not affect the test results of the Rapid SARS-CoV-2 Antigen Test Card. We will continue to evaluate additional mutation variants on an ongoing basis.

Nucleocapsid protein mutation locus	Corresponding strains	Endemic regions
D3L, R203K, G204R, S235F	20B/501Y.V1, VOC 202012/01, or B.1.1.7 lineage	United Kingdom
Q384H	C.1.1, etc.	Africa
S202N	A23.1	Asia and Africa
L230F	B.1.1.7	Oceania
S197L	A.2.5, etc.	Spain
D103Y	B.1.1.7	UK
T205I	B.1.351	South Africa
P13L	C.37, etc.	India, Singapore and Oceania
P80R, R203K, G204R, I292T		Brazil
A12G, T205I	B.1.525	New York City
N T205I, N T391I		California
P80R, RG203KR	P.1	Japan and Brazil
D63G, R203M, D377Y	B.1.617.2	India
A119S, RG203KR, M234I	P.2	Brazil
A12G, T205I	B.1.525	Nigeria

RG203KR	P.3	The Philippines
P199L, M234I	B.1.526	USA
R203M, D377Y	B.1.617.1	India
P67S, R203M, D377Y	B.1.617.3	India
G18S, A119S, A217S, M234I, E367Q	B.1.618	India
I292T, RG203KR		
P13L, S197L		
A220V		
S194L		
A208G		
RG203KR, K375N		
P67S, P199L, D377Y		
P67S, P199L, Q389L		
D3Y, R203M, D377Y	B.1.617	India
A376T, M234I		
T205I, M234I		

XIAMEN BOSON BIOTECH CO., LTD.



Jun. 18, 2021